Adult Polycystic Kidney Disease. Polycystic kidney, autosomal dominant Polycystic kidney, adult type
Conditions
Interventions
Intervention 1: Levodopa 50 mg capsule three times daily for 7 days
Domperidone 20 mg to reduce nausea used 30 minutes before Levodopa dose for 7 days. Intervention 2: Levodopa 100 mg capsule, three times daily for 7 days
Domperidone 20 mg to reduce nausea used 30 minutes before levodopa dose for 7 days. Intervention 3: control, placebo capsule three times daily for 7 days
domperidone 20 mg also used in this group to simulate drug group.
Treatment - Drugs
Placebo
Levodopa 50 mg capsule three times daily for 7 days
Domperidone 20 mg to reduce nausea used 30 minutes before Levodopa dose for 7 days
Levodopa 100 mg capsule, three times daily for 7 days
Domperidone 20 mg to reduce nausea used 30 minutes before levodopa dose for 7 days
control, placebo capsule three times daily for 7 days
domperidone 20 mg also used in this group to simulate drug group
Sponsors
The Dean, College of Pharmacy, University of Baghdad
Eligibility
Sex/Gender
All
Age
25 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: adult type polycystic kidney disease with borderline hypertension; Control group inclusion criteria are essential borderline hypertension without any secondary cause. Exclusion criteria are: Pregnancy, lactation, diabetes mellitus, myocardial infarction, angina, arrhythmias, renal transplantation, renal failure, serum creatinin more than 3mg/dL, dialysis, sever hypertension, recieving antihypertensive drugs.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Pressure. Timepoint: 0 hour, 2 hours, 7 days. Method of measurement: mercury sphygmomanometer.;Serum Nitric Oxide. Timepoint: 0 hour, 7 days. Method of measurement: serum detection by Greiss reaction (colorimetric). | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate. Timepoint: 0 hour, 2 hour, 7 days. Method of measurement: radial pulse method.;Assymetric dimethylarginine. Timepoint: 0 hour, 7 days. Method of measurement: serum samples by ELISA.;Serum Creatinin. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Urea. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Calcium. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Sodium. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Potassium. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Albumin. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Alanine Aminotransferase. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Aspartate Aminotransferase. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Alkaline Phosphatase. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Total Bilirubin. Timepoint: 0 hour, 7 days. Method of measurement: serum sample by ready made kit.;Body Mass Index. Timepoint: baseline. Method of measurement: Weight (kg)/Height (sequare meter). | — |
Countries
Iraq
Contacts
Public ContactSarmed H. Kathem
College of Pharmacy-University of Baghdad; College of Pharmacy-University of Toledo
Outcome results
None listed